Great Location
Competitive Salary
Performance Bonuses

12-month Undergraduate Placement - Immuno-oncology Therapeutic Area

Vacancy Salary £Competitive
Vacancy Location Cambridge
Mergefield Title {Mergefield Value}
Mergefield Title {Mergefield Value}

This is a Temporary, Full Time vacancy that will close in {x} days (x will be populated when viewing published adverts).

Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s platforms have been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.

In vitro assays to assess the mechanism of action of therapeutics are an essential part of the cancer drug discovery process.  Detailed in vitro assays also allow for analysis of drug molecules before use in tumour models in vivo, potentially reducing the requirement for animals (3Rs).  However, tumours are complex three-dimensional structures, with multiple cell types present, which makes accurate in vitro analysis tricky. 

Kymab have generated coculture assays of human cancer spheroids with immune cells, which allow for analysis of immune cell infiltration into the tumour using the Incucyte imaging system.  These assays replicate some features of the tumour microenvironment (TME) in vitro and can be modulated by therapeutic antibodies. However, the TME is a very complex 3-dimensional structure, with multiple cell types present, many of which have immuno-suppressive properties. Therefore, this project aims to develop and compare new cell-based assays in a 2D and 3D format introducing additional cell types to the existing assays, to more accurately represent the TME, and to allow the investigation of a wide range of therapeutic targets.

Key Responsibilities:

The student will be based within the Immuno-oncology Therapeutic Area (I-O TA) and learn a range of in vitro techniques, including but not limited to:

  • Culture of tumour-reactive T cells and other immune cell types
  • Isolation of primary cell
  • Tumour cell cytotoxicity assays
  • Real-time image analysis of 2-D and 3-D cultures
  • Multi-colour flow cytometry 

The student will also contribute to the overall I-O TA objectives and attend team and wider company meetings to gain exposure to the Discovery and Development process. 

We are a young, passionate and determined company.

We want to succeed in our aims to make a difference in healthcare and make better medicines using our unique technologies.

Our headquarters are in Cambridge, UK, on the Babraham Research Campus, an established bioscience campus, home to more than 60 companies.

Since we were founded, our team has grown to more than 180 people. It’s an invigorating environment where our teams work closely and collaboratively to help us all to achieve our aims.

You’ll find your role at Kymab exciting, interesting and stimulating, with the opportunity to interact with a diverse range of colleagues, both internally and externally.

Great Location

Competitive Salaries

Performance Bonuses

Share Plan

Healthcare Cover

Life & Income Insurance

Alternatively, apply with...


Published

2 hours ago

Closing

14 Days
Apply Now